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ABSTRACT 36 
Background: Clostridioides difficile infection (CDI) is a risk factor for bloodstream infections 37 
(BSI). Fecal microbiota transplantation (FMT) is more effective than antibiotics in treating 38 
recurrent CDI, but its efficacy in preventing CDI-related BSI is uncertain. 39 
Objective: To assess incidence of primary BSI in patients with recurrent CDI treated with FMT 40 
compared with patients treated with antibiotics.  41 
Design: Prospective cohort study.  FMT and antibiotic treated patients were matched using 42 
propensity score. 43 
Setting: Single academic medical center. 44 
Patients: 290 inpatients with recurrent CDI; 57 patients per treatment in matched cohort. 45 
Interventions: FMT or antibiotics.  46 
Measurements: Our primary outcome was the development of primary BSI within a 90-day 47 
follow-up. Secondary outcomes were length of hospitalization, and overall survival (OS) at 90 days. 48 
Results: 109 patients were treated with FMT, and 181 received antibiotics. Five patients in the 49 
FMT group and 40 in the antibiotic group developed BSI. Due to differences in the patients treated 50 
with FMT and antibiotics in a number of baseline characteristics including the number of 51 
recurrences and CDI severity, comparative analyses were limited to the matched cohort. Subjects in 52 
the FMT group experienced a 23% lower risk of developing BSI (95% confidence interval 10-53 
35%), 14 fewer days of hospitalization (95% confidence interval 9-20 days), and a 32% increase in 54 
OS (95% confidence interval 16-47%) compared with the antibiotic group. 55 
Limitations: Non-randomized study with potential for unmeasured/residual confounding. Limited 56 
generalizability of the propensity score-matched cohort.  57 
Conclusion: In a propensity score-matched cohort, patients with recurrent CDI treated with FMT 58 
were less likely to develop primary BSI.  59 
Funding Source: None.60 
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INTRODUCTION 61 
 62 
 Clostridioides difficile (previously called Clostridium difficile) infection (CDI) has become a 63 
major burden for healthcare systems, accounting for nearly 29,000 deaths/year in the United States 64 
(US) (1–3). The recent burden of CDI can be mostly explained by its rise in incidence, severity, 65 
mortality, and increased likelihood of recurrence (3-4). After a first episode of CDI, almost 20% of 66 
patients are likely to recur, and the risk of a further recurrence can be even higher (5). Recurrences 67 
contribute to the nearly $5 billion/year costs of CDI in the US, which includes longer 68 
hospitalization, and increased morbidity and mortality (3).  69 
 As recurrent CDI (rCDI) is often refractory to antibiotics, it is more likely than primary 70 
infection to be associated with life-threatening complications, including pseudomembranous colitis, 71 
toxic megacolon, need for colectomy, shock, perforation, bloodstream infection (BSI), and death 72 
(6). A substantial proportion of patients with CDI are likely to develop BSIs, which are mostly 73 
caused by intestinal microbes, and could lead to death in more than 50% of patients (7). The 74 
pathogenesis of this complication could be related to C. difficile itself, which may promote 75 
microbial translocation (8). Some evidence suggests that vancomycin therapy, which suppresses 76 
most anaerobic bacteria, could also be associated with this complication (7,8). This favours 77 
intestinal colonization by healthcare-associated pathogens, including vancomycin-resistant 78 
Enterococci (VRE) and Candida spp. (9,10). In support of this, independent risk factors for BSI 79 
secondary to CDI include ribotype 027, recurrent or severe disease, and vancomycin regimens 80 
higher than 500mg/day (7,8). 81 
 Fecal microbiota transplantation (FMT) aims to restore the normal composition of gut 82 
microbiota. FMT is superior to vancomycin in treating CDI (11–13) and is recommended to manage 83 
recurrences (14–16). FMT could also be a promising approach for severe CDI (17–20) and C. 84 
difficile ribotype 027 (21). In theory, the restoration of healthy microbiota through FMT might also 85 
prevent CDI-associated BSI via several mechanisms, including cure of the infection, avoiding need 86 
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for vancomycin, and decrease in antibiotic resistance gene expression in the gut resistome of the 87 
patient. This could decrease the incidence of BSI related to multi-drug resistant (MDR) bacteria 88 
(22). To date, however, there are neither clinical nor pre-clinical data to support this hypothesis. 89 
Our aim was therefore to assess the incidence of primary BSIs in a cohort of patients with rCDI 90 
treated with either FMT or antibiotics.  91 
92 
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METHODS 93 
 94 
Study design and patients 95 
 This was a single-center, prospective cohort study, reported following STrengthening the 96 
Reporting of OBservational studies in Epidemiology (STROBE) guidelines (23). All patients with 97 
rCDI who were hospitalized from July 2013 to May 2018 at the Fondazione Policlinico 98 
Universitario “A. Gemelli”, a tertiary care center based in Rome, Italy, were considered for 99 
inclusion.  100 
 Patients admitted to our hospital with a diagnosis of rCDI, following treatment of their first 101 
infection at another center, and those who developed a CDI recurrence during hospitalization at our 102 
center were eligible for inclusion. Thus, only patients who experienced their first observable 103 
episode of rCDI at our hospital were considered, while patients with a second recurrence following 104 
treatment for an initial CDI recurrence provided at our hospital were excluded. Other exclusion 105 
criteria were: refusal of informed consent; patients aged <18 years; and patients who developed 106 
secondary BSI from a known source. We excluded patients with a first episode of CDI, as FMT is 107 
not recommended in this situation (16), and those considered unfit for FMT to avoid selection bias.  108 
 The following data were recorded for each patient: age; gender; comorbidities assessed with 109 
the Charlson comorbidity index (24); development of bacterial, fungal, or polymicrobial BSI; date 110 
of death; length of hospital stay; number of previous CDI recurrences; severity of CDI (i.e., mild, 111 
severe, and fulminant as defined in Appendix); hospitalization or stay in a long-term care unit in the 112 
previous 90 days; admission to an intensive care unit (ICU) in the previous 90 days; MDR infection 113 
in the previous 90 days; antibiotic therapy in the previous 30 days; treatment provided for CDI 114 
(FMT or antibiotics); and insertion of any of a central venous catether (CVC), urinary catheter, or 115 
percutaneous endoscopic gastrostomy during hospitalization and before treatment.  116 
 Antibiotic regimens were categorized by class, administration route, duration, and dosages. 117 
Responsible physicians chose antibiotic regimens based on recommendations from the European 118 
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Society of Clinical Microbiology and Infectious Disease for the management of CDI (15). FMT, 119 
including donor selection, manufacturing of fecal infusates, and fecal delivery, was performed 120 
according to international guidelines (16). Blood cultures were performed if patients developed 121 
pyrexia (body temperature >38°C) or other signs or symptoms considered potentially attributable to 122 
sepsis. Participants were followed up with weekly visits or telephone calls from study enrollment 123 
until 90 days after the end of treatment. Definitions of CDI recurrence and BSI used in the study, 124 
and description of microbiological analyses and of our FMT protocol, are provided in the 125 
Appendix. 126 
 127 
Outcomes 128 
 Our primary outcome was the development of primary BSI from any organism after 129 
treatment for rCDI, and within a 90-day follow-up period. Secondary outcomes were length of 130 
hospitalization and overall survival (OS) at 90 days.  131 
 132 
Data analysis and statistics 133 
 For continuous variables, data were expressed as means with a standard deviation (SD) and 134 
median and interquartile range. For categorical variables, data were expressed as numbers and 135 
percentages. The difference in means or proportions in the demographic and clinical characteristics 136 
was examined using the standardized difference Cohen’s d (25). There is no universally 137 
acknowledged value that demonstrates balanced data, but 10% is recommended as a reasonable 138 
cutoff for unbalance (26). The difference in means or proportions in the outcome data was 139 
examined using the difference and 95% confidence interval (CI). 140 
 We used propensity score matching to match comparison and intervention respondents to 141 
create a more valid and counterfactual comparison group (27). The propensity score was the 142 
probability of treatment with FMT based on the person’s age, gender, number of CDI recurrences, 143 
severity of CDI, Charlson index, receipt of hospital or long-term care in the last 90 days, receipt of 144 
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antibiotics in the last 30 days, and insertion of any CVC or urinary catheter, using probit regression. 145 
Common support was used by dropping FMT cases whose propensity score was higher than the 146 
maximum or less than the minimum propensity score of the control group. The one-to-one nearest 147 
neighbor matching was done without caliper and without replacement, and ties did not exist. 148 
Although differences remained between the FMT and antibiotic patients in the matched sample, we 149 
did not repeat the matching process due to the already decreased number of patients who could be 150 
included (57/109 (52%) FMT patients and 57/181 (31%) antibiotic patients). After matching, the 151 
analysis was restricted to matched participants in the control and FMT groups. OS was evaluated 152 
using a Kaplan-Meier survivor function.   153 
Statistical analyses were performed with SPSS version 20.0 (SPSS Inc., Chicago, IL., USA) 154 
and Stata Statistical Software: Release 14 (StataCorp LP, College Station, TX., USA). The function 155 
psmatch2 was used for propensity matching. 156 
 157 
Role of the funding source 158 
None 159 
160 
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RESULTS 161 
 162 
Demographic and clinical characteristics of patients at baseline 163 
 Three-hundred and twenty-eight subjects with rCDI, who where hospitalized from July 2013 164 
through May 2018 at our hospital, were evalutated for recruitment. Most had been treated with 165 
either oral vancomycin or metronidazole, and only a minority with fidaxomicin, at their first 166 
episode of CDI. Thirty-eight patients were excluded for the following reasons: 25 subjects 167 
developed a secondary BSI from a known source (urinary sepsis: 12 patients; sepsis from CVC: 168 
eight patients; pulmonary sepsis: five patients); seven subjects were <18 years old; and six subjects 169 
were considered unfit for FMT. Data from the remaining 290 subjects (F=180, M=110, mean age 170 
75 years) were analyzed. Of them, 109 patients (38%) were treated with FMT and 181 (62%) 171 
received antibiotic therapy.  172 
 In the antibiotic group, the following drugs and regimens were used for 10 days: pulsed oral 173 
vancomycin 125 mg q.i.d. (n=63); pulsed oral vancomycin 250 mg q.i.d. (n=41); oral metronidazole 174 
500 mg t.i.d. plus pulsed oral vancomycin 125 mg q.i.d. (n= 25); oral metronidazole 500 mg t.i.d. 175 
(n= 24); fidaxomicin 200 mg b.i.d. (n= 11); pulsed oral vancomycin 500 mg q.i.d. (n=9); tapered 176 
oral vancomycin regimen (n=8). 177 
 There was a large difference in the number of previous CDI recurrences between the two 178 
groups (mean 2.82 in FMT group compared with 1.23 in the antibiotic group). Eighty percent of 179 
those treated with antibiotics had one recurrence of CDI, compared with 19% of the FMT group. 180 
The distribution of the number of recurrences in the two populations is detailed in Table 1. Thirty-181 
five (32%) patients in the FMT group presented with severe CDI, compared with 39 (22%) patients 182 
in the antibiotic group. Thirteen patients in both the FMT group (12%) and antibiotic group (7%) 183 
had fulminant disease. Seventeen (16%) and eleven (6%) patients had a CVC at enrollment in the 184 
FMT and antibiotic groups respectively. Twenty-six (24%) patients had a urinary catheter at 185 
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enrollment in the FMT group and seventy-four (41%) in the antibiotic group. There were also 186 
differences in gender and Charlson comorbidity index at baseline between the two groups (Table 1). 187 
 A higher rate of patients in the FMT group (n=106) experienced sustained cure of CDI after 188 
treatment than patients in the antibiotic group (n=69) (97% vs 38%), similar to the results in another 189 
study from our group (90% vs 26%).12 All patients whose CDI recurred once again after treatment 190 
were offered rescue therapy with FMT, fidaxomicin, or tapered vancomycin, based on the 191 
responsible physician’s decision. No patients in the FMT group underwent surgery (colectomy or 192 
loop ileostomy) for overwhelming CDI, compared with 14 in the antibiotic group (0% vs 8%). 193 
 In the propensity score matching group, matched on a one-to-one basis, there were 57 pairs 194 
with no ties. Fifty-two patients treated with FMT (48%) were excluded as they exceeded the 195 
common support criteria. Using the standardized difference and a 10% cut-off, the FMT group 196 
patients were younger, had a lower Charlson comorbidity index, a greater proportion of patients 197 
with a mild clinical picture of CDI, a lower proportion with only one CDI recurrence, and a higher 198 
proportion with CVC at enrolment. Figure 1 shows the distribution of the frequency of propensity 199 
scores in the two groups.  200 
 201 
Development of BSI at 90 days 202 
 Table 2 summarizes outcome data. Overall, 45 patients developed BSI (16%) during the 90-203 
day follow-up; five (5%) treated with FMT, and 40 (22%) with antibiotics. Five (5%) patients in the 204 
FMT group and 28 (16%) in the antibiotic group developed a bacterial BSI. No patients in the FMT 205 
group and 7 (12%) in the antibiotic group developed a fungal BSI. One patient in the FMT group 206 
and one in the antibiotic group developed a polymicrobial BSI (1% in each). Pathogens responsible 207 
for BSIs are shown in Table 3. Of the 11 patients, who received fidaxomycin to treat CDI, four 208 
developed BSI. In the propensity score matched cohort, two patients in the FMT group and 15 in 209 
the antibiotic group developed BSI during follow-up (4% vs 26%, difference of 23%, 95% CI 10-210 
35%).  211 
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Length of hospitalization 212 
  In the whole cohort, mean length of hospitalization was 13.3 days in patients treated with 213 
FMT and 29.7 days in those treated with antibiotics. In the propensity score matched cohort, 214 
patients in the FMT group experienced a significantly shorter mean length of hospitalization (mean 215 
13.4 days vs 27.8 days, difference 14 days 95% CI 9-20 days).  216 
 217 
Overall survival at 90 days  218 
 In the whole cohort, 79 of 290 patients (27%) died during the 90-day follow-up period, 21 219 
(7%) of them due to BSI (all in the antibiotic cohort). Causes of death in the remaining 58 patients 220 
were: deterioration of clinical condition due to overwhelming CDI (n=15, three in the FMT cohort 221 
and 12 in the antibiotic cohort); complications after surgery for CDI (n=11, all in the antibiotic 222 
cohort); ischemic heart disease (n=10, five in the FMT cohort and five in the antibiotic cohort); 223 
ischemic cerebrovascular disease (n=9, one in the FMT cohort and eight in the antibiotic cohort); 224 
cancer (n=3, one in the FMT cohort and two in the antibiotic cohort); pulmonary failure (n=3, all in 225 
the antibiotic cohort); acute-on-chronic kidney failure (n=3, all in the antibiotic cohort); variceal 226 
bleeding (n=2, one in the FMT cohort and one in the antibiotic cohort); and acute-on-chronic liver 227 
failure (n=2, all in the antibiotic cohort). 228 
 Fifty-eight patients (73%) died within 30 days from the end of treatment. Five of these had 229 
been treated with FMT, and 53 with antibiotics. All were inpatients at the time of death. None of the 230 
11 patients who died due to complications of surgery for overwhelming CDI had developed BSI. 231 
The other 21 patients (27%) died between 31 and 90 days after the end of treatment; four were in 232 
the FMT group and 17 in the antibiotic group. Ninety-day OS for the whole cohort was 73%, with 233 
100 (92%) patients alive in the FMT group, and 111 (61%) in the antibiotic group.  234 
 In the propensity-matched cohort, six (11%) patients in the FMT group and 24 (42%) in the 235 
antibiotic group died during the 90-day follow-up period, eight (7%) of them because of BSI and 236 
seven (12%) due to fungal infection. Most of these patients died within 30 days from the end of 237 
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treatment, three in the FMT group versus 15 in the antibiotic group. All were inpatients at the time 238 
of death. The other 10 patients died between 31 and 90 days after the end of treatment, three in the 239 
FMT group versus seven in the antibiotic group. Ninety-day OS for the propensity-matched cohort 240 
was higher in the FMT group compared with the antibiotic group (n=51 (89%) vs n=33 (58%), 241 
difference 32% (95% CI 16-47%)). Figure 2 shows OS in the propensity-matched cohort.  242 
243 
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DISCUSSION 244 
 245 
 A considerable proportion of patients with CDI can develop a primary BSI, which is caused 246 
mainly by intestinal microbes (7,8). Some evidence suggests that this complication could contribute 247 
to the global burden of CDI by increasing length of hospital stay and mortality (7). Moreover, 248 
primary BSI is known to be the second most burdensome hospital-associated infection in Europe 249 
(28), due to both inpatient costs, and also needs that arise after discharge (29). Antibiotics 250 
commonly used to treat CDI, such as vancomycin, may not prevent the risk of BSI in these patients 251 
(9,10,30,31). In our study, patients with rCDI who received FMT were less likely to develop a 252 
primary BSI, and related complications, including death. There were notable differences between 253 
the FMT and antibiotic treated groups in the original cohort, particularly in relation to the number 254 
of CDI recurrences. We used propensity scores matched on nearest neighbor to reduce the 255 
differences between groups. However, there was not a perfect overlap in propensity scores, and 256 
imbalance in several baseline characteristics persisted between the propensity-score matched 257 
groups. This leaves the possibility that the two groups of patients are different, due to confounding, 258 
and we must be cautious in interpreting the findings. 259 
In the propensity-matched cohort, with 57 patients per treatment, of the 17 patients who 260 
developed BSI from any organism, two were treated with FMT and 15 with antibiotics, with a 261 
significantly lower incidence in the FMT group. Patients from the matched cohort treated with FMT 262 
also experienced a significantly shorter mean hospitalization than those treated with antibiotics. 263 
Although we did not perform a cost-effectiveness analysis, this could have implications for the cost 264 
of managing patients with rCDI, already evaluated in dedicated health economics studies (32,33). 265 
Another noteworthy finding observed in the propensity matched cohort was the significantly higher 266 
OS at 90 days in patients treated with FMT. Most patients died within 30 days from the end of 267 
treatment, many because of CDI complications, and all were hospitalized at the time of death. There 268 
were small differences in death rates between the two groups between 30 and 90 days, when several 269 
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patients were discharged. These findings suggest that the longer 90-day OS experienced by patients 270 
in the FMT group is attributable to cure of CDI, leading to an improvement in their clinical 271 
condition. The higher number of post-surgical deaths in the antibiotic group could have increased 272 
the difference in death rates between groups. However, all surgical patients underwent surgery for 273 
overwhelming CDI, and not for other indications, so these events were always dependent on the 274 
clinical severity of CDI. 275 
 As an explanation for our findings, FMT could act through several therapeutic pathways to 276 
prevent BSI, and related complications, in patients with CDI. FMT may directly reduce this risk, by 277 
curing CDI. C. difficile toxins are known to damage the gut barrier and increase intestinal 278 
permeability (34–36), thus favouring translocation of pathogens into the bloodstream. Moreover, 279 
severe CDI has been identified as a risk factor for BSI (7,8), suggesting that severe inflammation 280 
could further increase gut permeability. FMT is recognized as a highly effective therapy for 281 
sustained cure of rCDI (11), and increasing evidence suggests that it could also be a reliable 282 
treatment for severe CDI (12,20,37,38). In our study, the significantly higher rate of patients cured 283 
by FMT, rather than by antibiotics, may have contributed to decrease intestinal permeability and to 284 
prevent translocation of microbes, and therefore the development of BSI. Additionally, CDI is 285 
known to promote colonization of the gut by Candida (39). By curing CDI, FMT may not only 286 
decrease the rate of bacterial BSI, but also of Candida-dependent systemic infections.  287 
 Another possible explanation for our findings is the avoidance of repeated cycles of 288 
vancomycin, due to cure of CDI by FMT. High-dose (>500 mg/day) oral vancomycin has been 289 
previously identified as a risk factor for BSI development, (7) and this finding could be explained 290 
by its effect on gut microbiota. Oral vancomycin was shown to decrease Firmicutes (including C. 291 
difficile) and to increase Proteobacteria in humans (40). The increase of Proteobacteria phylum 292 
could lead to the overgrowth of bacteria commonly responsible for primary BSI, including K. 293 
pneumoniae or E. coli. Moreover, the sustained use of vancomycin could foster the development of 294 
resistant bacteria, such as VRE. In our study, both K. pneumoniae and VRE were found to be 295 
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commonly responsible for BSI, confirming this hypothesis. Oral vancomycin has also been shown 296 
to promote intestinal colonization by Candida species (41), which could explain the reduction in 297 
fungal BSIs seen in the FMT group. 298 
 Finally, the restoration of healthy microbiota through FMT could decrease the gut resistome, 299 
which is the expression of antibiotic resistance genes by the gut microbiota, thus increasing the 300 
likelihood of developing a BSI from MDR bacteria (42). FMT has been shown to be associated with 301 
a decrease in antibiotic-resistant bacteria in a prospective pilot study (22). Intensive antibiotic 302 
therapies could promote both the development of CDI, and the selection of antibiotic-resistant 303 
bacteria, which are more difficult to eradicate, and are more likely to lead to BSI. 304 
 Our study has some limitations, due to its observational nature, which prevent us from 305 
drawing definitive conclusions. On average, patients treated with FMT presented with worse 306 
clinical conditions than those with antibiotics. We aimed to reduce this bias by performing 307 
propensity score matching. However, differences between the propensity score matched comparison 308 
groups remain with respect to several baseline characteristics. The propensity-matching method 309 
removed 52 (48%) of the FMT-treated and 124 (69%) of the antibiotic-treated patients from the 310 
analysis, which may limit the generalizability of this analyzed sub-cohort to the population of 311 
people with rCDI. 312 
We did not collect stool samples from patients before and after the treatments to assess 313 
shifts in gut microbiota composition, nor did we assess the cost-effectiveness of using FMT in 314 
rCDI. Additionally, we did not include in the analysis some baseline parameters, including 315 
immunosuppression, liver or kidney disease, or previous chemotherapy or radiotherapy, which 316 
might have influenced the development of BSI. Another limitation could be that fidaxomicin was 317 
used in only a minority of patients in the antibiotic group; it has been suggested to be less likely 318 
than vancomycin to promote colonization by Candida species and VRE (41). This can be explained 319 
by the high costs of fidaxomicin, its lack of availability in Italy at the start of our study, and the 320 
availability of FMT as a reliable therapeutic alternative, which has also been recently shown to be 321 
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superior to fidaxomicin in patients with rCDI (43). Finally, the observational study design could 322 
have introduced bias into our analysis, due to other differences among patients that we did not 323 
measure, and which may have driven the choice of treatment by responsible physicians. Future 324 
studies that use a randomized controlled design, with microbial analysis, and that collect economic 325 
data are required to confirm the efficacy and cost-effectiveness of FMT in preventing CDI and its 326 
related complications. 327 
 In conclusion, in our propensity-score matched cohort, patients with rCDI treated with FMT 328 
were less likely to develop primary BSI, experienced a shorter duration of hospitalization, and had a 329 
reduction in the risk of overall mortality within 90 days, compared with those treated with 330 
antibiotics. Should our results be confirmed by larger, randomized studies, FMT could be 331 
considered an effective treatment option to both rCDI and prevent some of its related complications, 332 
including BSI. 333 
334 
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Table 1. Demographic and clinical characteristics of the patients in the original cohort and in the propensity score matched cohort. 539 
 Original cohort After propensity score matching 
 
Variable 
Treated with 
FMT 
Treated with 
antibiotics 
Standardized 
difference 
Treated with 
FMT 
Treated with 
antibiotics 
Standardized 
difference 
Number 109 181  57 57  
Mean age in years (SD) 75.3 (12.2) 74.7 (13.1) -5% 73.7 (14.7) 76.3 (11.3) 20% 
Gender 
 Male (%) 
 Female (%) 
 
37 (34) 
72 (66) 
 
75 (41) 
106 (59) 
 
19% 
 
23 (40) 
34 (60) 
 
21 (37) 
36 (63) 
 
7% 
Mean Charlson Comorbidity Index (SD)  4.3 (1.9) 3.9 (1.7) -19% 3.9 (1.9) 4.2 (1.5) 21% 
Mean number of CDI recurrences (SD) 
Median number of CDI recurrences (IQR) 
Number of CDI recurrences (%) 
  1 
 2 
 3 
 4 
 5+ 
2.82 (1.34) 
3 (2-4) 
 
21 (19) 
25 (23) 
30 (28) 
23 (21) 
10 (9) 
1.23 (0.48) 
1 (1-1) 
 
145 (80) 
31 (17) 
5 (3) 
0 (0) 
0 (0) 
178% 1.88 (0.78) 
2 (1-2) 
 
21 (37) 
22 (39) 
14 (25) 
0 (0) 
0 (0) 
1.61 (0.65) 
2 (1-2) 
 
27 (47) 
25 (44) 
5 (9) 
0 (0) 
0 (0) 
-37% 
Clinical picture of CDI  
 Mild (%) 
 
61 (56) 
 
129 (71) 
 
32% 
 
34 (60) 
 
28 (49) 
 
22% 
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 Severe (%) 
 Fulminant (%) 
35 (32) 
13 (12) 
39 (22) 
13 (7) 
18 (32) 
5 (9) 
22 (39) 
7 (12)) 
CVC at enrollment  
 Yes (%) 
 No (%) 
 
17 (16) 
92 (84) 
 
11 (6) 
170 (94) 
 
31% 
 
8 (14) 
49 (86) 
 
5 (9) 
52 (91) 
 
17% 
Urinary catheter at enrollment  
 Yes (%) 
 No (%) 
 
26 (24) 
83 (76) 
 
74 (41) 
107 (59) 
 
37% 
 
14 (25) 
43 (75) 
 
16 (28) 
41 (72) 
 
8% 
Hospitalization within 90 days before 
enrollment 
 Yes (%) 
 No (%) 
 
 
66 (61) 
43 (39) 
 
 
108 (60) 
73 (40) 
 
 
2% 
 
 
35 (61) 
22 (39) 
 
 
37 (65) 
20 (35) 
 
 
7% 
Surgery within 30 days before enrollment 
 Yes (%) 
 No (%) 
 
14 (13) 
95 (87) 
 
22 (12) 
159 (88) 
 
2% 
 
9 (16) 
48 (84) 
 
7 (12) 
50 (88) 
 
10% 
Antibiotics within 30 days before enrollment 
 Yes (%) 
 No (%) 
 
60 (55) 
49 (45) 
 
95 (53) 
86 (47) 
 
5% 
 
35 (61) 
22 (61) 
 
33 (58) 
24 (42) 
 
7% 
MDR infection within 90 days before 
enrollment 
 
 
 
 
 
 
 
 
 
 
 
 
Ianiro et al. Page 29 of 42 
 
 
 Yes (%) 
 No (%) 
13 (12) 
96 (88) 
13 (7) 
168 (93) 
16% 3 (5) 
54 (95) 
3 (5) 
54 (95) 
0% 
ICU admission within 90 days before 
enrollment 
 Yes (%) 
 No (%) 
 
 
6 (6) 
103 (94) 
 
 
10 (6) 
171 (94) 
 
 
0% 
 
 
2 (4) 
55 (96) 
 
 
1 (2) 
56 (98) 
 
 
11% 
 540 
CDI= C. difficile infection; CVC=central venous catheter; FMT= fecal microbiota transplantation; ICU= Intensive care unit; IQR = Interquartile 541 
range; MDR= multi-drug resistant; SD= standard deviation.  542 
543 
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Table 2: Outcome data in the original cohort and in the propensity score matched cohort. 544 
  Original cohort After propensity score matching 
Outcome level Variable Treated with 
FMT 
Treated with 
antibiotics 
Difference Treated 
with FMT 
Treated with 
antibiotics 
Difference 95% confidence 
interval 
 Number 109 181  57 57   
Primary Bloodstream infection (%) 
 Polymicrobial 
 Bacterial 
 Fungal 
5 (5) 
1 (1) 
5 (5) 
0 (0) 
40 (22) 
1 (1) 
28 (15) 
7 (12) 
16% 2 (4) 
0 (0) 
2 (4) 
0 (0) 
15 (26) 
0 (0) 
8 (14) 
7 (12) 
23% 10-35% 
Secondary Length of hospitalization in days 
 Mean (SD) 
 Median (interquartile range)  
 
13.3 (14.8) 
8 (2-20) 
 
29.7 (22.6) 
22 (14-39) 
 
24 
 
13.4 (13.7) 
9 (2-21) 
 
27.8 (17.6) 
22 (14-40) 
 
14 
 
9-20 
Alive after 90 days (%) 
 Total deaths within 0-90 days 
 Death within days 0-30 
 Death within days 31-90 
100 (92) 
9 (8) 
5 
4 
111 (61) 
70 (39) 
53 
17 
30% 51 (89) 
6 (11) 
3 
3 
33 (58) 
24 (42) 
15 
7 
32% 16-47% 
Ianiro et al. Page 31 of 42 
 
 
Table 3. Involved organisms in bloodstream infections in the original study cohort. 545 
Microbes Total number  
of patients  
FMT 
group 
Antibiotic  
group 
Bacteria 
XDR Acinetobacter baumannii 
Escherichia coli 
Enterococcus faecalis 
VR Enterococcus faecium 
Klebsiella oxytoca 
Klebsiella pneumoniae  
CRE Klebsiella pneumoniae 
ESBL Klebsiella pneumoniae 
Staphylococcus spp 
Staphylococcus aureus 
MR Staphylococcus aureus 
Proteus mirabilis 
XDR Proteus mirabilis 
Corinebacterium spp 
Total 
 
2 
3 
3 
3 
1 
3 
3 
1 
7 
1 
1 
1 
1 
1 
31 
 
0 
0 
1 
0 
1 
1 
0 
1 
1 
0 
0 
0 
0 
0 
5 
 
2 
3 
2 
3 
0 
2 
3 
0 
6 
1 
1 
1 
1 
1 
26 
Fungi 
Candida albicans 
Candida parapsilosis 
Candida tropicalis 
Total  
 
9 
4 
1 
14 
 
0 
0 
0 
0 
 
9 
4 
1 
14 
Overall 45* 5 40 
 546 
* 12 of 45 patients developed a polymicrobial bloodstream infection (bloodstream infections from 547 
multiple bacteria in 10 patients; bloodstream infections from fungal and bacterial organisms in 2 548 
patients). CRE= carbapenem-resistant Enterobacteriaceae; ESBL= extended-spectrum beta-549 
lactamase; FMT= fecal microbiota transplantation; MR= methicillin-resistant; XDR= extensively 550 
drug-resistant. 551 
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Figure 1: Frequency distribution of propensity scores (probability of treatment with FMT) 552 
for the propensity score matched cohort in patients treated with FMT and patients treated 553 
with antibiotics. 554 
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Figure 2: Overall survival at 90 days in 57 patients treated with FMT compared with 57 559 
patients treated with antibiotics matched by propensity score. 560 
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 562 
FMT= fecal microbiota transplantation. Shaded area displays 95% confidence interval 563 
564 
Ianiro et al. Page 34 of 42 
 
 
APPENDIX 565 
 566 
Definitions 567 
 RCDI was defined as diarrhea and positivity for the C. difficile toxin stool test within 8 568 
weeks from the end of the previous antibiotic treatment (15). Patients were classified, based on their 569 
clinical picture, according to the latest recommendations from the Infectious Disease Society of 570 
America for the management of CDI (44). Criteria for defining non-severe CDI were leukocytosis 571 
with a white blood cell count of ≤15 000 cells/mL and a serum creatinine level <1.5 mg/dL. Severe 572 
CDI was defined by leukocytosis with a white blood cell count of ≥15 000 cells/mL or a serum 573 
creatinine level >1.5 mg/dL. Finally, fulminant CDI was diagnosed in the presence of hypotension 574 
or shock, ileus, or megacolon (44). Nosocomial CDI was defined as CDI diagnosed more than 48 575 
hours after hospital admission. 576 
 An episode of BSI was defined, according to recommendations from the Centers for Disease 577 
Control and Prevention, as the presence of one or more recognized pathogens in at least one blood 578 
culture or, for potential skin contaminants, the positivity of two or more separate blood cultures 579 
within 48 hours, in the presence of at least two signs or symptoms of a systemic inflammatory 580 
response (45). Candidaemia was defined as one or more blood cultures positive for Candida genus, 581 
together with clinical signs and symptoms of infection (46). 582 
 A primary BSI was defined as one occurring without a known source of infection. A 583 
secondary BSI was defined as one arising from a recognized source. CVCs were accounted to be 584 
the likely source of infection if blood cultures from the catheter lumen, but not from a peripheral 585 
vein, were positive within 2 hours (47).  586 
 587 
Microbiological analyses 588 
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 Stool tests for C. difficile toxin were performed using Liaison® C.difficile GDH-Toxin A/B 589 
kit (DiaSorin Inc. 1951 Northwestern Avenue Stillwater. MN, USA). All tests were performed in 590 
the microbiology laboratory of the hospital. 591 
 To identify pathogens for the diagnosis of BSI, blood samples were collected for culture and 592 
inoculated in BACTEC bottles (Becton Dickinson Instrument Systems, Sparks, Md.) or Bact/Alert 593 
bottles (bioMérieux, Marcy l’Etoile, France) and incubated for up to 5 days in the BACTEC FX or 594 
Bact/Alert VIRTUO automated blood culture (BC) instruments. When the growth index of a bottle 595 
was positive, broth aliquots from each positive BC bottle were collected for standard method (Gram 596 
staining, and culture-based method) and direct method using MALDI BioTyper (Bruker Daltonik 597 
GmbH, Leipzig, Germany). 598 
 599 
Description of the FMT protocol. 600 
The FMT protocol included the following steps: 1) selection and screening of donors; 2) 601 
manufacturing of fecal infusate; 3) fecal infusion procedure. 602 
 603 
Selection of donors 604 
The selection of donors was performed by two authors (G. C. and G. I.) following protocols 605 
recommended by international guidelines (16). Healthy volunteers younger than 50 years of age 606 
were initially screened through a specific questionnaire to exclude: 607 
A) Possible risk factors for potentially transmittable diseases due to their medical history 608 
and lifestyle habits, including: history of, or known exposure to, HIV, HBV, HCV, syphilis, human 609 
T-lymphotropic virus I and II, malaria, trypanosomiasis, tuberculosis; systemic infections not 610 
controlled at the time of donation; use of illegal drugs; risky sexual behavior; previous reception of 611 
tissue/organ transplant; previous (less than 12 months) reception of blood products; recent (less than 612 
6 months) needle stick accident; recent (less than 6 months) body tattoo, piercing, earring, or 613 
acupuncture; recent medical treatment in poorly hygienic conditions; risk of transmission of 614 
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diseases caused by prions; recent parasitosis or infection from rotavirus, Giardia lamblia, or other 615 
microbes with gastrointestinal involvement; recent (less than 6 months) travel in tropical countries, 616 
countries at high risk of communicable diseases, or traveller’s diarrhea; recent (less than 6 months) 617 
history of vaccination with a live attenuated virus; healthcare or animal workers. 618 
B) Gastrointestinal, metabolic and neurological disordes, including: irritable bowel 619 
syndrome, inflammatory bowel disease, functional chronic constipation, celiac disease, or other 620 
chronic gastrointestinal diseases; chronic, systemic autoimmune disorders with gastrointestinal 621 
involvement; gastrointestinal cancer or polyposis (or high risk for these disorders); recent diarrhea 622 
or hematochezia; neurological disorders and/or psychiatric conditions; overweight or obesity (body 623 
mass index >25) 624 
C) The use of drugs that could impair the composition of the intestinal microbiota, 625 
including: recent (<3 months) exposure to antibiotics, immunosuppressants, chemotherapeuthics, or 626 
chronic therapy with proton pump inhibitors.  627 
All potential donors who passed the questionnaire underwent blood exams (including: 628 
serology for cytomegalovirus, Epstein-Barr virus, hepatitis A, hepatitis B, hepatitis C, and hepatitis 629 
E viruses, syphilis, HIV-1 and HIV-2 viruses, Entamoeba histolytica; complete blood count, C-630 
reactive protein, erythrocyte sedimentation rate, albumin, creatinine, electrolytes, 631 
aminotransferases, bilirubin, gamma-glutamyltransferase, alkaline phosphatase) and stool exams 632 
(including: culture and toxin for C. difficile; detection of enteric pathogens, including Salmonella, 633 
Shigella, Campylobacter, Escherichia coli O157 H7, Yersinia, vancomycin-resistant enterococci, 634 
methicillin-resistant Staphylococcus aureus, or Gram-negative multidrug-resistant bacteria; 635 
Norovirus; antigens and/or acid fast staining for Giardia lamblia and Criptosporidium parvum; 636 
Protozoa (including Blastocystis hominis) and helminths; faecal occult blood testing) to exclude 637 
potentially transmittable diseases.  638 
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Finally, candidates underwent a further questionnaire the day of each donation to exclude 639 
any recent acute gastrointestinal illness or symptom, newly contracted infections, use of new drugs, 640 
or other potentially harmful situations for the patient. 641 
The assignment of faecal infusates from healthy donors to patients was done randomly, 642 
without any specific recipient-donor match, as suggested by international guidelines (16). 643 
 644 
Manufacturing of faecal infusate 645 
 All faecal infusate samples were prepared in the microbiology laboratory of our hospital by 646 
L.M., following manufacturing protocols recommended by international guidelines (16). We used 647 
either fresh or frozen feces, using at least 50g of feces for each sample. Feces were collected by the 648 
donor on the day of infusion and rapidly transported to our hospital. In the hospital’s microbiology 649 
laboratory, the feces were diluted with at least 250 mL of sterile saline (0.9%). The deriving 650 
solution was blended, and the supernatant strained and poured into a sterile container. For frozen 651 
samples, glycerol was added up to a final concentration of 10% before freezing, and the samples 652 
were stored at -80°C. On the day of fecal infusion, frozen infusates were thawed in a warm (37°C) 653 
water bath. 654 
 655 
Fecal infusion procedure 656 
 The fecal infusion procedure included the following steps: a 3-day pre-treatment with oral 657 
vancomycin (250 mg by mouth four times a day), followed by bowel cleansing with 2L of macrogol 658 
per day for 2 days, and then fecal infusion from healthy donors by colonoscopy, as previously 659 
described (12). All procedures were performed by two expert endoscopists (G. C., G. I), using 660 
peediatric colonoscopes and carbon dioxide insufflation. The infusate was delivered within 6 hours 661 
after donor supply (if fresh feces were used) or after thawing (if frozen feces were used), through 662 
the operative channel of the scope after reaching the most proximal point of the colon, using 50mL 663 
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syringes filled with the infusate during colonoscopy. Finally, the patients were monitored in the 664 
recovery room of the endoscopy center for 2 to 3 hours after the procedure. 665 
 666 
667 
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Patients excluded from the propensity-matched cohort 668 
The propensity score matched cohort excluded a set of patients from the analysis. The 669 
characteristics of this excluded cohort are shown in Supplementary Table 1. The main difference 670 
between the two treatment groups, in the group excluded by the propensity matching, is that 95% of 671 
the patients in the antibiotic-treated group had only one CDI recurrence, compared with the FMT 672 
group, where 100% had two or more CDI recurrences. 673 
 674 
675 
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Supplementary Table 1: Baseline and outcome data for those excluded from the propensity 676 
score matched cohort. 677 
Variable Treated with FMT Treated with antibiotics 
Number 52 124 
Mean age in years (SD) 77.1 (8.64) 74.1 (13.81) 
Gender 
 Male (%) 
 Female (%) 
 
40 (77) 
12 (23) 
 
54 (44) 
70 (56) 
Mean Charlson Comorbidity Index (SD)  4.39 (1.77) 3.76 (1.81) 
Number of CDI recurrences (%) 
  1 
 2 
 3 
 4 
 5+ 
 
0 (0) 
3 (6) 
16 (31) 
23 (44) 
10 (19) 
 
118 (95) 
6 (5) 
0 (0) 
0 (0) 
0 (0) 
Clinical picture of CDI  
 Mild (%) 
 Severe (%) 
 Fulminant (%) 
 
27 (52) 
17 (24) 
8 (15) 
 
101 (82) 
17 (14) 
6 (5) 
CVC at enrollment  
 Yes (%) 
 No (%) 
 
9 (17) 
43 (83) 
 
6 (5) 
118 (95) 
Urinary catheter at enrollment  
 Yes (%) 
 No (%) 
 
12 (23) 
40 (77) 
 
58 (47) 
66 (53) 
Hospitalized within 90 days before enrollment 
 Yes (%) 
 No (%) 
 
31 (60) 
21 (40) 
 
71 (57) 
53 (43) 
Surgery within 30 days before enrollment 
 Yes (%) 
 
5 (10) 
 
15 (12) 
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 No (%) 47 (90) 109 (88) 
Antibiotics within 30 days before enrollment 
 Yes (%) 
 No (%) 
 
25 (48) 
27 (52) 
 
62 (50) 
62 (50) 
MDR infection within 90 days before enrollment 
 Yes (%) 
 No (%) 
 
10 (19) 
42 (81) 
 
10 (8) 
114 (92) 
ICU admission within 90 days before enrollment 
 Yes (%) 
 No (%) 
 
4 (8) 
48 (92) 
 
9 (7) 
115 (93) 
Bloodstream infection (%) 
 Bacterial 
 Fungal 
3 (6) 
3 (6) 
1 (2) 
25 (20) 
20 (16) 
6 (5) 
Length of hospitalization in days 
 Mean (SD) 
 Median (interquartile range)  
 
13.3 (16.1) 
6 (2-19.5) 
 
30.5 (24.6) 
22.5 (14-38) 
Alive after 90 days (%) 
 Total deaths 0-90 days 
 Death within days 0-30 
 Death within days 31-90 
 
3 (6) 
2 (4) 
1 (2) 
 
78 (63) 
36 (29) 
42 (34) 
CDI= C. difficile infection; CVC=central venous catheter; FMT= fecal microbiota transplantation; 678 
ICU= Intensive care unit; MDR= multi-drug resistant; SD= standard deviation.  679 
680 
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